ZGN-1061

A battered Zafgen seeks strategic options, prophesying ongoing study will unlikely lift FDA hold on diabetes drug
Endpoints
Thu, 09/5/19 - 10:32 am
Zafgen
diabetes
FDA
ZGN-1061
Zafgen has something to cheer as diabetes drug makes the cut in PhII study, quelling cardio safety fears
Endpoints
Thu, 01/17/19 - 09:40 am
Zafgen
diabetes
clinical trials
ZGN-1061
FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns
BioSpace
Mon, 11/26/18 - 12:30 pm
Zafgen
clinical trials
FDA
diabetes
ZGN-1061
type 2 diabetes
Zafgen starts comeback with first data on replacement weight loss drug
Fierce Biotech
Fri, 05/5/17 - 10:27 am
Zafgen
obesity
beloranib
ZGN-1061
Zafgen shares drop more than 40% as drug focus shifted
Marketwatch
Tue, 07/19/16 - 10:05 pm
Zafgen
beloranib
ZGN-1061
obesity